Kasherman Lawrence, Siu Derrick Ho Wai, Woodford Rachel, Harris Carole A
Department of Medical Oncology, St. George Hospital, Kogarah, NSW 2217, Australia.
St. George and Sutherland Clinical Schools, University of New South Wales, Sydney, NSW 2217, Australia.
Cancers (Basel). 2022 Mar 9;14(6):1406. doi: 10.3390/cancers14061406.
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-stage renal cell carcinomas (RCC), but more recently, combination regimens with immune checkpoint inhibitors have demonstrated better outcomes. Despite this, the majority of affected patients still eventually experience progressive disease due to therapeutic resistance mechanisms, and there remains a need to develop novel therapeutic strategies. This article will review the synergistic mechanisms behind angiogenesis and immunomodulation in the tumor microenvironment and discuss the pre-clinical and clinical evidence for both clear-cell and non-clear-cell RCC, exploring opportunities for future growth in this exciting area of drug development.
血管生成抑制剂已被纳入晚期肾细胞癌（RCC）的标准治疗手段，但最近，免疫检查点抑制剂联合方案已显示出更好的疗效。尽管如此，由于治疗耐药机制，大多数受影响的患者最终仍会出现疾病进展，因此仍需要开发新的治疗策略。本文将综述肿瘤微环境中血管生成与免疫调节之间的协同机制，并讨论透明细胞和非透明细胞RCC的临床前和临床证据，探索这一令人兴奋的药物研发领域未来的发展机会。
Zotero 插件